Market Closed -
Other stock markets
|
After market 02:39:10 pm | |||
39.26 EUR | -2.34% | 39.29 | +0.08% |
Summary
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company appears to be poorly valued given its net asset value.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company is in debt and has limited leeway for investment
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+3.42% | 12.62B | A- | ||
+14.40% | 81.68B | C+ | ||
-28.98% | 69.23B | B- | ||
+9.72% | 29.08B | C+ | ||
-11.54% | 16.88B | B | ||
-0.43% | 16.85B | A- | ||
-0.97% | 15.15B | A- | ||
+29.49% | 12.47B | B- | ||
-30.70% | 11.89B | - | - | |
-6.19% | 11.68B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- FME Stock
- Ratings Fresenius Medical Care AG